Evotec And Arix Bridge Gap With Latest Cancer Funding
Arix Biosciences and Evotec AG have formed an academic partnership to accelerate research discoveries at the Fred Hutchison Cancer Research Center.
You may also be interested in...
Partnership will use Carna’s proprietary lipid kinase drug discovery platform, bringing another aspect to Gilead’s IO efforts. Catalent continues expansion by acquiring Novavax R&D assets; Genfit licenses elafibranor in China to Terns.
As it narrows focus to core therapeutic areas ahead of acquiring Shire, Takeda sends uterine fibroid and endometriosis rights to compatriot firm ASKA. Zai Lab and Crescendo team up on antibody candidate for inflammatory indications.
Evotec's hybrid drug discovery model continues to attract pharma partners and generate internal assets using what its CEO calls a "diversified seed sowing" business approach.